Cellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference
February 08, 2018 08:15 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma
February 07, 2018 08:15 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers
January 29, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Biosciences to Participate at Noble Capital Markets’ Fourteenth Annual Investor Conference
January 22, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Biosciences to Participate at Biotech Showcase 2018
January 04, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers
December 14, 2017 08:43 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort in Phase 2 Trial of CLR 131
December 06, 2017 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Biosciences to Present at the 10th Annual LD Micro Main Event
November 20, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
Madison, Wis., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Biosciences Reports Third Quarter 2017 Financial and Corporate Performance
November 09, 2017 16:01 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today reported financial...
Cellectar Announces Updated Median Overall Survival of 26.2 Months from Cohort 1 of CLR 131 Phase 1 Trial in Advanced Multiple Myeloma
November 07, 2017 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company (the “company”), today announces that the...